CS/NSE/BSE/PR/2015-2016
November 2, 2015

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: SUVEN - EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

With reference to above subject, please find enclosed Press Release of our company titled "**Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in Munich, Germany**"

This is for your information and records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

K Hanumantha Rao
Company Secretary

News Release

Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in Munich, Germany

HYDERABAD, INDIA (November 02, 2015) – Several exciting new results and data presentations from Suven's portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Bio-Europe 2015 in Munich, Germany, November 2- 4, 2015.

BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. BIO-Europe's partneringONE®, enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

During BIO-Europe 2015 partnering conference, Suven lined up several face to face meetings with major Pharma, Biotech and financial companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently** in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited
CIN: L24110TG1989PLC009713
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor
Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com